Related references
Note: Only part of the references are listed.Plasminogen Activator Inhibitor-1 Antagonist TM5484 Attenuates Demyelination and Axonal Degeneration in a Mice Model of Multiple Sclerosis
Nicolas Pelisch et al.
PLOS ONE (2015)
Plasminogen Activator Inhibitor-1 Antagonist TM5441 Attenuates Nω-Nitro-L-Arginine Methyl Ester-Induced Hypertension and Vascular Senescence
Amanda E. Boe et al.
CIRCULATION (2013)
Plasminogen activator inhibitor-1 inhibitors: a patent review (2006-present)
Yolanda M. Fortenberry
EXPERT OPINION ON THERAPEUTIC PATENTS (2013)
Targeting Plasminogen Activator Inhibitor-1 Inhibits Angiogenesis and Tumor Growth in a Human Cancer Xenograft Model
Evan Gomes-Giacoia et al.
MOLECULAR CANCER THERAPEUTICS (2013)
SK-216, an Inhibitor of Plasminogen Activator Inhibitor-1, Limits Tumor Progression and Angiogenesis
Takeshi Masuda et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Three Decades of Research on Plasminogen Activator Inhibitor-1: A Multifaceted Serpin
Paul J. Declerck et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2013)
Therapeutic Value of Small Molecule Inhibitor to Plasminogen Activator Inhibitor-1 for Lung Fibrosis
Wen-Tan Huang et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2012)
Protumorigenic Activity of Plasminogen Activator Inhibitor-1 Through an Antiapoptotic Function
Hua Fang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
The hyperfibrinolytic state of mice with combined thrombin-activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor-1 gene deficiency is critically dependent on TAFI deficiency
E. Vercauteren et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2012)
The Biochemistry, Physiology and Pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo
Britt Van de Craen et al.
THROMBOSIS RESEARCH (2012)
The first report of uncontrollable subchorionic and retroplacental haemorrhage inducing preterm labour in complete PAI-1 deficiency in a human
Takayuki Iwaki et al.
THROMBOSIS RESEARCH (2012)
Structure-Activity Relationships of New N-Acylanthranilic Acid Derivatives as Plasminogen Activator Inhibitor-1 Inhibitors
Nagahisa Yamaoka et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2011)
A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates
Yuko Izuhara et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2010)
Inhibition of plasminogen activator inhibitor-1 - Its mechanism and effectiveness on coagulation and fibrosis
Yuko Izuhara et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis
Khalid Bajou et al.
CANCER CELL (2008)
The plasminogen activator inhibitor paradox in cancer
Bernd R. Binder et al.
IMMUNOLOGY LETTERS (2008)
Mechanism of inactivation of plasminogen activator inhibitor-1 by a small molecule inhibitory
Natalia V. Gorlatova et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
The Plasminogen Activator System and Cancer
Brandon McMahon et al.
PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS (2007)
A novel function of plasminogen activator inhibitor-1 in modulation of the AKT pathway in wild-type and plasminogen activator inhibitor-1-deficient endothelial cells
Rashna D. Balsara et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Multimodal imaging analysis of tumor progression and bone resorption in a murine cancer model
Maria L. Mouchess et al.
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY (2006)
Plasminogen activation:: a mediator of vascular smooth muscle cell apoptosis in atherosclerotic plaques
P Rossignol et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2006)
Inhibition of apoptosis and caspase-3 in vascular smooth muscle cells by plasminogen activator inhibitor type-1
YB Chen et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2004)
Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: Design, synthesis, and preclinical characterization
H Elokdah et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin:: Implications for antiangiogenic strategies
K Bajou et al.
JOURNAL OF CELL BIOLOGY (2001)
Share Paper
